Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025;21(3):e1573403X343784.
doi: 10.2174/011573403X343784241115055037.

Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report

Rundi Qi  1   2 , Hailei Liu  1 , Xin Li  2 , Minglong Chen  1
Affiliations
Case Reports

Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report

Rundi Qi et al. Curr Cardiol Rev. 2025.

Abstract

Introduction: Managing hypertriglyceridemia-induced acute pancreatitis (HTG-AP) can be challenging, particularly due to the need for rapid triglyceride reduction to below 500mg/dL (5.645 mmol/L).

Case report: This is a case describing a 39-year-old female patient who presented to the Emergency Department with acute abdominal pain resulting from severe HTG-AP. However, under conventional therapy with oral lipid-lowering drugs, the triglyceride levels remained uncontrolled. Oral moderate-intensity statins could not only reduce low-density lipoprotein cholesterol (LDLc) by 25%-50%. However, increasing the dose could not further reduce blood lipids while increasing the risk of liver damage. After the administration of proprotein convertase subtilisin/ kexin type 9 inhibitor (PCSK9i), the triglyceride levels were well controlled with no additional side effects, and the symptoms of the patients were completely relieved.

Conclusion: In cases of unsatisfactory lipid control under conventional therapy, PCSK9i may offer a viable option for managing HTG-AP.

Keywords: Hypertriglyceridemia; acute abdominal pain.; acute pancreatitis; low-density lipoprotein cholesterol; proprotein convertase subtilisin/kexin type 9 inhibitor; triglyceride reduction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Similar articles

See all similar articles

References

    1. Colvin S.D., Smith E.N., Morgan D.E., Porter K.K. Acute pancreatitis: An update on the revised Atlanta classification. Abdom. Radiol. (N.Y.) 2020;45(5):1222–1231. doi: 10.1007/s00261-019-02214-w. - DOI - PubMed
    1. Gliem N., Ammer-Herrmenau C., Ellenrieder V., Neesse A. Management of severe acute pancreatitis: An update. Digestion. 2021;102(4):503–507. doi: 10.1159/000506830. - DOI - PMC - PubMed
    1. Chang C.C., Hsieh Y.Y., Tsai H.D., Yang T.C., Yeh L.S., Hsu T.Y. Acute pancreatitis in pregnancy. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61(2):85–92. - PubMed
    1. Scherer J., Singh V.P., Pitchumoni C.S., Yadav D. Issues in hypertriglyceridemic pancreatitis: An update. J. Clin. Gastroenterol. 2014;48(3):195–203. doi: 10.1097/01.mcg.0000436438.60145.5a. - DOI - PMC - PubMed
    1. Papachristou G.I., Machicado J.D., Stevens T., et al. Acute pancreatitis patient registry to examine novel therapies in clinical experience (APPRENTICE): An international, multicenter consortium for the study of acute pancreatitis. Ann. Gastroenterol. 2017;30(1):106–113. - PMC - PubMed

Publication types

LinkOut - more resources